Slide 1: Cyclopharm Limited Preliminary 1H 2016 Results Investor Roadshow
For personal use only Cyclopharm Limited A profitable and growing market leader in nuclear medical imaging and lung healthcare Preliminary 1H 2016 Results Investor Roadshow July 2016 1
Slide 2: Our Strategy
Our Strategy For personal use only CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by: 1. Attaining approval
Slide 3: Contents
For personal use only Contents James McBrayer, Managing Director • Company Overview • Introduction • Preliminary 1H 2016 Highlights • Product Overview and Growth Opportunities ― Technegas ― Untralute • Strategic Priorities and Outlook 3
Slide 4: CYC's Fast Facts
CYC’s 10 Fast Facts For personal use only 1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with multiple revenue streams consisting of: service income, capital equipment and 84% of sales generated from single patient consumables 2. Techneg
Slide 5: Introduction
Introduction For personal use only In 2015 Cyclopharm made significant progress on our strategy that delivered a substantial increase in shareholder value through the global manufacture and supply of innovative nuclear medicine technologies • Well established, profitable and fiscally disciplined bio
Slide 6: Our Technology
Our Technology For personal use only Manufacturer and distributor • Invented in 1986 of pulmonary ventilation • Track record of growing revenue, imaging devices and profits and cash flows equipment • USFDA trials for sales in US progressing • Functional lung ventilation imaging agent historically us
Slide 7: 1H FY 2016 Highlights
1H FY 2016 Highlights For personal use only • Sales of $6.1 million • EBIT $0.8 million • Payment of recurring dividends • Strong cashflow from operations significantly strengthened the balance sheet, with cash reserves at 30 June totalling $6.8 million after repayment of debt • USFDA clinical trial
Slide 8: 1H FY2016 Preliminary Financial Comparison
1H FY2016 Preliminary Financial Comparison For personal use only Preliminary Actual H1 Half Year ended 30 June Inc/(Dec) % Change H1 2016 2015 Sales Revenue #039;000 6,148 5,078 1,070 21% Gross Margin #039;000 5,093 3,985 1,108 28% Gross Margin % 82.8% 78.5% 4.3% Profit before tax and finance costs #039;000
Slide 9: Growth Drivers: Technegas – Expanding the Global footprint
Growth Drivers: Technegas – Expanding the Global footprint For personal use only • Technegas sold in 55 countries − Europe is the largest regional market for Technegas − In 2014 Canada became largest country market for Technegas surpassing France • Over 3,500,000 patient studies since 1986 • 1,500 T
Slide 10: Technegas – USFDA clinical trial program
Technegas – USFDA clinical trial program For personal use only USA Market Size: • Half the world’s nuclear medicine departments are in the USA • USA represents a potential base Pulmonary Embolism market of 480,000 patients per annum. (Current Rest of the World volumes = 200,000 patients per annum) S
Slide 11: Ultralute
UltraluteTM For personal use only Product overview Technology features • Disruptive Technology – changes 60 years • Enables a user to extend the usable life of of how radiopharmaceuticals are a Mo99 Generator manufactured • Allows the user to purchase a smaller • Extends the effective use of Mo99 Mo
Slide 12: Ultralute Generation overview
UltraluteTM Generation overview For personal use only • Designed for the end user application • There are 4,000 Mo99 • Introduced to market Q4 2015 with revenues GEN 1 commencing H1 2017 generators sold worldwide each week. • Designed for radiopharmacy application • Development will commence in 2017
Slide 13: 2016 Strategic Priorities and Outlook
2016 Strategic Priorities and Outlook For personal use only Strategic Goals & Guidance Activity Timeframe United States • Proceeded on an independent path to USA market approval Q2 2016 FDA approval • USFDA clinical trial program commenced Q2 2016 • Relocate the Cyclopharm manufacturing premises and
Slide 14: Appendix Section
For personal use only Cyclopharm Limited Appendix Section • Cyclopharm History • Technegas 2015 Financial Results • Growth Opportunities and Key Performance Indicators • Evolution of Functional Lung Ventilation Imaging • Technegas • Ultralute • MMI • Disclaimer 14
Slide 15: Our History
Our History For personal use only 1984 1992 2000 2001 2007 2013 Technegas European markets Vita Life Sciences USFDA Technegas Plus UltraluteTM discovered and established acquires program initiated generator launched technology commercialised Tetley Medical for Technegas established 1985 1995 2000 20
Slide 16: Technegas FY15 Performance
Technegas FY15 Performance For personal use only Second consecutive year of record results • Another record financial result in FY15 • A third consecutive year Year ended 31 December ($000’s) 2015 Change 2014 Change 2013 of record sales expected Technegas Results: Sales Revenue in 2016 for Technegas
Slide 17: Group Balance Sheet
Group Balance Sheet For personal use only Strong financial position • Improved cash position driven by strong cash flows from operations Year ended 31 December ($000’s) 2015 2014 • Capacity to fund growth Cash 6,445 3,268 initiatives and ongoing Other current assets 6,653 5,582 R&D Non-current Asset
Slide 18: Cash Flow
Cash Flow For personal use only • Strong cash reserves Growing cash generation available to fund near to medium term growth opportunities Year ended 31 December 2015 2014 2013 Operating Activities 4,154,834 4,468,780 1,185,110 • Investment Activities in 2015 included FDA, Ultralute & Investing Activ
Slide 19: Growth Opportunities and Key Performance Indicators
Growth Opportunities and Key Performance Indicators For personal use only Technegas USA • The USA represents the single largest market with half of the world’s nuclear medicine departments located there • Existing market for PE in the USA equates to ~480,000 patients per annum • First priority follo
Slide 20: Growth Opportunities and Key Performance Indicators
Growth Opportunities and Key Performance Indicators For personal use only Ultralute MMI Cyclopet Market • Europe targeted as the Revenue Volumes closely aligned with Molecular Following competition from Penetration primary market to launch the hospital. Continued double Imaging government owned ente
Slide 21: Evolution of Functional Lung Ventilation Imaging
Evolution of Functional Lung Ventilation Imaging For personal use only • Improvements in 3D imaging techniques, hybrid imaging and the advent of analytical software have dramatically improved the sensitivity and specificity in functional lung imaging with Technegas • Traditionally used in the diagno
Slide 22: Technegas – Global Indication Expansion
Technegas – Global Indication Expansion For personal use only Targeting Chronic Obstructive Additional indication and applications Pulmonary Disease (COPD) market – Asthma, Lung Reduction and CTEPH* Evaluating the effectiveness of Technegas in Technegas can provide the clinician the ability to early
Slide 23: Technegas Indication expansion – COPD
Technegas Indication expansion – COPD For personal use only The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE) It is estimated that by 2020, COPD will be the 4th highest cause of death globally. By 2030 COPD will be the 3rd highes
Slide 24: Technegas – The Canadian Case Study
Technegas – The Canadian Case Study For personal use only The Generator : Consumable Relationship • Canada is our largest single country market with 12 consecutive years of PAS growth • Canada represents a strong indicator of USA acceptance • Xe133 rapidly displaced by early adopters • Direct correl
Slide 25: Ultralute Targeting direct users of Mo99
UltraluteTM Targeting direct users of Mo99 For personal use only • UltraluteTM v1 is targeted at the clinical end-user market that sources Mo99 Generators directly from manufacturers • The European Mo99 generator market is completely Direct • Ultralute registration in the EU has been determined to b
Slide 26: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only • Joint venture with: CT MRI PET • 50% Alfred Health Solutions • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities • State of the art research platform Cardiac CT Ultra-sound SPECT • Growth and profitability linked t
Slide 27: Disclaimer
For personal use only Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Building 75 Business & Technology Park New Illawarra Road The presentation include certain sta